Analysis
Zai Lab Limited (Nasdaq: ZLAB), the Shanghai- and Cambridge-based biopharmaceutical company -- not to be confused with the Chinese AI lab Z.ai -- has agreed to raise approximately $250 million in gross proceeds through a private investment in public equity, or PIPE, according to Pulse 2.0. The deal prices 11.34 million American Depositary Shares at $22.04 each, with each ADS representing 10 ordinary shares, and is expected to close around October 27, 2026.
TCGX is leading the round, with abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Sirenia Capital Management, Wellington Management and Woodline Partners participating. Leerink Partners is acting as placement agent.
“Zai Lab is betting an ADC approach to the same target can compete with those bispecific mechanisms.”
The proceeds are earmarked for zocilurtatug pelitecan, an investigational antibody-drug conjugate targeting Delta-like ligand 3 (DLL3), a protein already validated as a cancer target: Amgen's DLL3-targeted bispecific Imdelltra won FDA approval in 2024 for small-cell lung cancer, and Boehringer Ingelheim has its own DLL3 asset, obrixtamig, in development. Zai Lab is betting an ADC approach to the same target can compete with those bispecific mechanisms.
The risk for existing shareholders: a PIPE dilutes immediately, and pricing 11.34 million new ADSs brings that dilution before zocilurtatug pelitecan has produced the clinical data that would justify the raise.
A PIPE at a fixed per-share price, rather than a straight secondary offering, usually signals a company wants committed, long-term biotech specialists on its cap table rather than index-fund turnover -- the roster of growth and crossover funds here fits that pattern.
